TIMP-1 Induces an EMT-Like Phenotypic Conversion in MDCK Cells Independent of Its MMP-Inhibitory Domain

Plasma Markers for Identifying Patients with Metastatic Melanoma

(2011) H. M. Kluger et al.   CLINICAL CANCER RESEARCH

Dynamic Interdomain Interactions Contribute to the Inhibition of Matrix Metalloproteinases by Tissue Inhibitors of Metalloproteinases

(2011) Albert G. Remacle et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Alteration of integrin-dependent adhesion and signaling in EMT-like MDCK cells established through overexpression of calreticulin

(2011) Yoshito Ihara et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Zeb1 is required for TrkB-induced epithelial-mesenchymal transition, anoikis resistance and metastasis

(2011) M A Smit et al.   ONCOGENE

The Intrinsic Protein Flexibility of Endogenous Protease Inhibitor TIMP-1 Controls Its Binding Interface and Affects Its Function

(2010) Moran Grossman et al.   BIOCHEMISTRY

Elevated plasma tissue inhibitor of metalloproteinase-1 levels predict decreased survival in castration-resistant prostate cancer patients

(2010) William K. Oh et al.   CANCER

Zeb1 and twist are more commonly expressed in metastatic than primary lung tumours and show inverse associations with claudins

(2010) H. Merikallio et al.   JOURNAL OF CLINICAL PATHOLOGY

The Chemokine Receptor CXCR4 and the Metalloproteinase MT1-MMP Are Mutually Required during Melanoma Metastasis to Lungs

(2009) Rubén A. Bartolomé et al.   AMERICAN JOURNAL OF PATHOLOGY

Disruption of E-Cadherin by Matrix Metalloproteinase Directly Mediates Epithelial-Mesenchymal Transition Downstream of Transforming Growth Factor-β1 in Renal Tubular Epithelial Cells

(2009) Guoping Zheng et al.   AMERICAN JOURNAL OF PATHOLOGY

Association between tumor tissue TIMP-1 levels and objective response to first-line chemotherapy in metastatic breast cancer

(2009) Marie Klintman et al.   BREAST CANCER RESEARCH AND TREATMENT

Tissue inhibitor metalloproteinase type-1 (TIMP-1), a novel cancer biomarker predicting response of adjuvant anthracycline-based chemotherapy in patients afflicted with primary breast cancer

(2009) Manfred Schmitt et al.   EUROPEAN JOURNAL OF CANCER

Low expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) in glioblastoma predicts longer patient survival

(2009) Charlotte Aaberg-Jessen et al.   JOURNAL OF NEURO-ONCOLOGY

Extracellular Remodelling During Oncogenic Ras-Induced Epithelial-Mesenchymal Transition Facilitates MDCK Cell Migration

(2009) Rommel A. Mathias et al.   JOURNAL OF PROTEOME RESEARCH

The prognostic value of TIMP-1 in multiple myeloma

(2009) Liliana Guedez et al.   LEUKEMIA RESEARCH

Global Gene Expression Profiling Of Human Pleural Mesotheliomas: Identification of Matrix Metalloproteinase 14 (MMP-14) as Potential Tumour Target

(2009) Stefania Crispi et al.   PLoS One

TIMP-1 as a tumor marker in breast cancer – An update

(2008) Sidse Ø Würtz et al.   ACTA ONCOLOGICA

A Large-Scale Study of MT1–MMP as a Marker for Isolated Tumor Cells in Peripheral Blood and Bone Marrow in Gastric Cancer Cases

(2008) Koshi Mimori et al.   ANNALS OF SURGICAL ONCOLOGY

Membrane-type-1 matrix metalloproteinase, matrix metalloproteinase 2, and tissue inhibitor of matrix proteinase 2 in prostate cancer: identification of patients with poor prognosis by immunohistochemistry

(2008) Dominique Trudel et al.   HUMAN PATHOLOGY

High preoperative plasma TIMP-1 is prognostic for early relapse in primary breast carcinoma

(2008) Paula Kuvaja et al.   INTERNATIONAL JOURNAL OF CANCER

Membrane Type 1 Matrix Metalloproteinase Induces Epithelial-to-Mesenchymal Transition in Prostate Cancer

(2008) Jian Cao et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Serum TIMP-1 and Response to the Aromatase Inhibitor Letrozole Versus Tamoxifen in Metastatic Breast Cancer

(2008) Allan Lipton et al.   JOURNAL OF CLINICAL ONCOLOGY